Peptide Bioavailability: Subcutaneous vs Oral vs Intranasal — What the Research Shows

Why most research peptides require injection, SubQ bioavailability data, intranasal BBB crossers, and oral peptides like BPC-157 and semaglutide explained.

TL;DR

• Route determines delivery — the same peptide by different routes can have vastly different efficacy
• SubQ injection typically achieves 75–100% bioavailability for most research peptides
• Intranasal administration is validated for small peptides that can cross the blood-brain barrier
• A small number of peptides (BPC-157, semaglutide via SNAC) have meaningful oral activity

Disclaimer: For educational and research purposes only — not medical advice.

Understanding how a peptide reaches its target tissue is just as important as selecting the compound itself. Two researchers using the same peptide at the same nominal dose can get entirely different results depending on administration route. This article breaks down the pharmacokinetic science behind subcutaneous, oral, and intranasal delivery — explaining why each works for certain compounds and fails for others.

Why Peptides Are Destroyed in the Gastrointestinal Tract

The gastrointestinal system is an extremely hostile environment for peptide molecules. The moment a peptide is swallowed, it encounters a cascade of enzymatic barriers designed precisely to break down protein and peptide structures into absorbable amino acids.

Gastric phase: Pepsin, activated by stomach acid (pH 1.5–3.5), cleaves peptide bonds at aromatic and large hydrophobic residues. Even brief exposure is sufficient to fragment most linear peptides into inactive pieces. Some cyclic or D-amino acid peptides resist pepsin better than standard L-amino acid sequences, but these represent a small minority of research compounds.

Intestinal phase: As chyme moves into the duodenum, pancreatic proteases (trypsin, chymotrypsin, elastase) continue degradation. Brush border peptidases on enterocyte membranes then cleave residual oligopeptides. By this point, most standard peptides have been reduced to di- and tripeptides or individual amino acids.

Absorption barrier: Even if a peptide fragment survives proteolysis, intestinal absorption is limited by molecular weight. Passive transcellular diffusion drops sharply above approximately 500 Da. Most research peptides fall in the 500–5,000 Da range, making passive absorption negligible. Paracellular transport through tight junctions is theoretically possible but exceedingly limited under normal conditions.

Molecular weight context: BPC-157 is 1,419 Da. TB-500 (fragment) is approximately 895 Da. CJC-1295 is 3,367 Da. Semaglutide is 4,113 Da. None of these would achieve meaningful systemic levels through a standard oral route without technological modification.

The practical consequence: researchers using oral administration of most peptides are likely receiving negligible systemic exposure. This is not speculation — it is well-characterized pharmacokinetics applied to peptide chemistry.

Subcutaneous Injection: The Reference Standard

SubQ injection deposits the compound into the hypodermis, the fatty tissue layer beneath the dermis. From here, diffusion into surrounding capillaries and lymphatics occurs gradually, creating a depot effect that smooths out peak concentrations and extends absorption time.

Bioavailability advantages: SubQ completely bypasses GI proteolysis. The hypodermis contains far lower enzymatic activity than the gut lumen, and peptidases in subcutaneous fluid are not a significant degradation pathway for most research peptides. Bioavailability from SubQ injection is typically cited at 75–100% depending on the compound, with many smaller peptides approaching the upper end.

Absorption kinetics: Unlike IV administration, which delivers immediate peak plasma levels, SubQ produces a gradual rise over 15–60 minutes for most peptides. This profile is actually desirable for compounds like GH secretagogues, where a pulsatile but not spike-dominated release pattern more closely mimics endogenous secretory patterns.

Practical technique factors: Injection depth matters. True SubQ requires needle penetration into fat, not intramuscular (IM) tissue. Incorrect depth can alter absorption kinetics. Injection site rotation prevents localized tissue reactions and ensures consistent absorption.

For most research purposes, SubQ injection is the default route and offers the best evidence base. See our beginner's injection guide for technique details.

Intranasal Administration: Small Peptides and the BBB Question

The nasal mucosa offers a genuinely interesting alternative route for select peptides. The olfactory epithelium in the upper nasal cavity is in direct contact with olfactory nerve fibers that project into the olfactory bulb — and from there, directly into the brain. This creates an anatomical pathway that partially bypasses the blood-brain barrier (BBB).

Size and lipophilicity requirements: For intranasal absorption, peptides ideally fall below 1,000 Da and have some degree of lipophilicity to penetrate nasal epithelial membranes. Both Semax (980 Da) and Selank (863 Da) meet these criteria. Russian clinical research with both compounds has used intranasal administration as the primary delivery method, and pharmacokinetic evidence suggests meaningful CNS activity via this route.

Semax intranasal research: Semax is an ACTH(4–7) analog that has been studied in Russia for cognitive function, neuroprotection, and stroke recovery. Intranasal administration is the standard in this literature, with doses of 400–1200 mcg per day in divided doses. The olfactory nerve route is thought to enable direct CNS penetration without requiring significant systemic levels.

Selank intranasal research: Selank, a tuftsin analog with anxiolytic and nootropic properties, has similarly been studied primarily via intranasal dosing. Given its anxiolytic mechanism, CNS delivery is the relevant endpoint, making nasal administration physiologically logical.

Limitations: Not all intranasal absorption is via the olfactory route. A substantial portion may be absorbed through nasal vasculature into systemic circulation, then cross the BBB (or not) depending on the compound's properties. Mucociliary clearance also limits contact time, making solution formulation and volume critical. Most researchers use 100–200 mcL per nostril per application.

For peptides primarily targeting the CNS, intranasal delivery deserves serious consideration over SubQ when compound size permits. See our Semax and Selank comparison for more on these compounds.

Oral Peptides: The Exceptions and the Technology

While the general rule is that peptides require injection, two notable exceptions warrant discussion: BPC-157 and semaglutide (oral formulation via SNAC technology).

BPC-157 oral stability: BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from human gastric juice protein. Its origin in gastric juice may partly explain its unusual resistance to acid and proteolytic degradation. Animal research has shown systemic and local GI effects from orally administered BPC-157, including healing of intestinal fistulas, colitis, and gastric ulcers. The oral route appears particularly relevant for GI-tract local effects, since the compound may act locally on gut tissue even without high systemic absorption. For systemic effects — particularly musculoskeletal applications — SubQ remains more pharmacokinetically reliable.

Semaglutide and SNAC technology: Oral semaglutide (Rybelsus) achieves a modest but clinically meaningful ~1% bioavailability through co-formulation with sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC). SNAC acts as a permeation enhancer that locally raises gastric pH around the tablet (protecting semaglutide from acid), increases membrane permeability, and promotes absorption directly through the gastric mucosa rather than the intestine. This is a pharmaceutical-grade proprietary formulation — not something achievable by simply swallowing a peptide capsule.

Cyclic and modified peptides: Certain modified peptides with D-amino acid substitutions, N-methylation, or cyclization show improved proteolytic resistance. This is an active area of pharmaceutical development, but most such compounds are not standard research peptides.

The takeaway: oral administration of research peptides is largely unreliable except for BPC-157 (with caveats) and pharmaceutical oral formulations with purpose-built delivery technology.

Choosing Your Route: Practical Framework

When selecting an administration route for a research peptide, the following hierarchy applies:

1. Follow the pharmacokinetic literature. If a compound has been studied by a specific route, that route has the most validated data. Deviating introduces uncertainty about actual exposure.

2. Match route to target tissue. For CNS targets, intranasal is worth considering for appropriately sized peptides. For systemic targets, SubQ is default. For GI-tract targets, oral BPC-157 may have a place.

3. Consider molecular weight and stability. Peptides above 1,500 Da have essentially zero meaningful oral bioavailability without specialized delivery technology. Peptides above ~1,000 Da have diminishing intranasal efficacy.

4. Account for reconstitution and formulation. SubQ requires sterile reconstitution and proper storage. Intranasal requires appropriate buffer pH and preservatives. Both require attention to sterility.

For a detailed overview of reconstitution methodology, see our peptide reconstitution guide.

Frequently Asked Questions

Q: Can I take BPC-157 orally instead of injecting? A: BPC-157 does show unusual oral stability compared to most peptides, and animal research supports oral dosing for GI-related applications. However, oral bioavailability figures for systemic exposure remain poorly characterized in human pharmacokinetic studies. For musculoskeletal or systemic applications where SubQ dosing has more established research backing, oral administration introduces uncertainty about the actual dose reaching systemic circulation. For gut-healing research applications, oral may be logically appropriate given local GI tissue contact.

Q: Why do some peptide vendors sell oral capsules if they don't work? A: Oral capsule sales for most peptides reflect commercial interest more than pharmacokinetic science. Some vendors market oral peptides with the rationale that localized GI effects are the target, which is only relevant for a narrow set of compounds. In most cases, researchers purchasing injectable peptides in capsule form for systemic effects are likely wasting the compound. Understanding this distinction is critical for interpreting research outcomes.

Q: Does IM injection differ from SubQ for peptides? A: Intramuscular injection delivers compound into highly vascularized muscle tissue, producing faster absorption and higher peak plasma concentrations than SubQ. For many research peptides, the difference in total bioavailability is small, but the kinetic profile differs. SubQ is generally preferred for peptides where a depot effect and gradual release is desirable (most GH secretagogues). IM may be preferred when rapid peak levels are sought, though this is less common in standard research protocols.

Q: How does nasal spray volume affect intranasal absorption? A: Volume is an important variable. Too small a volume reduces delivered dose; too large a volume floods the nasal cavity, increases posterior drainage into the nasopharynx (reducing contact time with the olfactory epithelium), and reduces absorption efficiency. Most intranasal peptide protocols use 100–200 mcL per nostril per application, with total daily doses divided into two or more administrations. Standard insulin syringes or dedicated nasal spray bottles calibrated to this volume are typically used.

Research tools for peptide dosing → Use the Peptide Calculator to convert doses across body weight and concentration

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions